#Spain #Madrid #Kelun-Biotech #sacituzumab tirumotecan #ESMO 2026

Kelun-Biotech at ESMO 2026

Overview

The prestigious European Society for Medical Oncology (ESMO) Congress is approaching, scheduled for October 23 to 27, 2026, in Madrid, Spain. This annual event is a hallmark in the oncology community, bringing together leading professionals to share advancements in cancer research and treatment strategies. This year, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. will present significant results from various clinical studies, particularly focusing on their targeted therapies.

Highlights of the Presentations

Kelun-Biotech will unveil data on two innovative antibody-drug conjugates (ADCs), including their flagship product, sacituzumab tirumotecan (sac-TMT), known commercially as 佳泰莱® and designated as SKB264/MK-2870. This ADC specifically targets the TROP2 protein, prevalent in several solid tumors. Notably, findings from two Phase III studies, OptiTROP-Lung04 and OptiTROP-Lung06, have been selected for oral presentations, highlighting Kelun’s commitment to addressing significant medical needs in oncology.

Key Clinical Trials

• - OptiTROP-Lung06 Study: This randomized Phase III trial compares sac-TMT combined with pembrolizumab to standard chemotherapy plus pembrolizumab in treating PD-L1 negative advanced non-squamous non-small cell lung cancer (NSCLC). The results are expected to shed light on the efficacy of this combination therapy, aiming to provide improved outcomes for patients with metastatic cancer.
• - OptiTROP-Lung04 Study: Another important trial focusing on patients with EGFR-mutated NSCLC who experienced progression after treatment with EGFR-TKI. This final overall survival analysis seeks to validate sac-TMT as a viable treatment option for this challenging patient population.

Both studies will be presented during a dedicated NSCLC session on October 25, drawing attention as proffered paper reports.

Additional Presentations

Further research involving sac-TMT will also be presented, including:

• - SKB500 Study: This Phase I trial investigates a novel B7-H3-targeted ADC for patients with extensive-stage small cell lung cancer, showcasing promising results in tackling this aggressive cancer type.
• - Breast Cancer Focus: The Phase III OptiTROP-Breast01 study will reveal crucial data on the use of sac-TMT in previously treated locally recurrent or metastatic triple-negative breast cancer.
• - Gynecological Cancers: Key findings from the TroFuse-005 study on sac-TMT usage in advanced endometrial cancer will also be highlighted at the ESMO Presidential Symposium on October 26.

About sacituzumab tirumotecan (sac-TMT)

Sac-TMT is a crucial product for Kelun-Biotech, representing a significant advancement in cancer therapy. It utilizes a unique bifunctional linker to deliver chemotherapy directly to tumor cells, thereby enhancing efficacy while minimizing side effects. This ADC has been approved in China for its usage in various cancer types, including breast and lung cancers, which reflects its potential impact on global therapeutic practices.

In recent developments, sac-TMT has obtained six Breakthrough Therapy Designations by the NMPA (National Medical Products Administration), emphasizing its favorable profile among oncologists and patients alike. Following an exclusive licensing agreement with MSD (Merck & Co., Inc.), the drug is now poised for global expansion beyond its home market.

Conclusion

Kelun-Biotech's presentation at ESMO 2026 marks a pivotal moment in the ongoing fight against cancer. With an array of significant clinical data set to be revealed, the company aims to demonstrate the potential of its innovative therapies to improve patient outcomes globally. As the medical community converges in Madrid, all eyes will be on Kelun-Biotech and its contributions to the future of oncology.